Viridian Therapeutics, Inc.\DE (VRDN) Cash & Equivalents (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Cash & Equivalents history runs 14 years deep, the most recent figure standing at $176.3 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 51.74% year-over-year to $176.3 million in Q1 2026; TTM through Mar 2026 was $176.3 million, a 51.74% increase from a year earlier, with the FY2025 full-year figure at $212.4 million, up 113.25% from the prior year.
• Cash & Equivalents fell to $176.3 million in Q1 2026 per VRDN's latest filing, from $212.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $344.2 million in Q3 2022 and bottomed at $30.9 million in Q1 2022.
• The 5-year median for Cash & Equivalents is $111.6 million (2023), against an average of $131.9 million.
• Across the five-year window, Cash & Equivalents soared 267.81% in 2022 and slumped 67.58% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $155.6 million in 2022, then slumped by 33.91% to $102.8 million in 2023, then slipped by 3.14% to $99.6 million in 2024, then surged by 113.25% to $212.4 million in 2025, then slipped by 16.97% to $176.3 million in 2026.
• Per Business Quant, the three latest VRDN Cash & Equivalents figures stand at $176.3 million (Q1 2026), $212.4 million (Q4 2025), and $169.6 million (Q3 2025).